Oncology

Latest News

The investigators found that tumor mutational burden and PD-L1 expression, which have traditionally been used as indicators of immunotherapy efficacy, had little predictive value for survival in this cohort. | Image credit: Dragana Gordic - stock.adobe.com

Predictive Model Forecasts Advanced NSCLC Outcomes

By Jared Kaltwasser

August 14th 2025

The newly developed model has an area under the curve of 0.807 for predicting progression-free survival.

Dordaviprone is indicated for recurrent H3 K27M-mutant diffuse midline glioma, an ultra-rare, aggressive brain tumor primarily affecting children. | Image credit: wladimir1804 - stock.adobe.com

FDA Approves Dordaviprone as First and Only Treatment for Aggressive Form of Glioma

By Rose McNulty

August 6th 2025

Gen Li, PhD, MBA, president and founder of Phesi

Real-World Data, Digital Patient Profiles Are Revolutionizing Trial Design, Patient Recruitment: Gen Li, PhD, MBA

By Pearl Steinzor
Gen Li, PhD, MBA

August 4th 2025

Value-based care. | Image Credit: irissca - stock.adobe.com

Legal Navigation Services Key to Addressing Disparities in Cancer Care

By Cameron Santoro

July 31st 2025

Radiotherapy can work synergistically with immunotherapy by reprogramming the tumor microenvironment. | Image credit: Crystallight-stock.adobe.com

Brain Radiotherapy Plus ICIs Boost Survival in SCLC With Brain Metastases

By Jared Kaltwasser

July 30th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Watch Now

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

Continuing Medical Education

View All

August 15th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology

August 15th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

December 30th 2015

Most-Read Articles From AJMC's Conference Coverage in 2015

Surabhi Dangi-Garimella, PhD

Studies that provided updates on new drug trials, sessions on value-based care, and the cost of healthcare, were most popular among readers of The American Journal of Managed Care.

December 29th 2015

Using Technology to Bring Palliative Care to the Patient's Doorstep

Surabhi Dangi-Garimella, PhD

After having launched a palliative care program in 2014, Cambia Health Solutions is now looking for ways to improve patient access to these tools that can improve a patient's quality of life.

December 29th 2015

Cost, Value of Cancer Drugs Take Center Stage in Current Issue of AJMC's Evidence-Based Oncology

One of the biggest stories of 2015 has been the cost of cancer drugs, which create vexing questions for payers and policymakers, as well as doctors and families. The tough choices being made today are the theme of the latest special issue of Evidence-Based Oncology, a publication of The American Journal of Managed Care.

December 28th 2015

Improving Cancer Trial Participation via Web-Based Interventions

Surabhi Dangi-Garimella, PhD

Patient awareness and educational support can improve their attitude as well as prepare them to make better informed decisions on clinical trial participation, a new study has found.

December 28th 2015

Report: Shkreli Arrest Prompts Cancer Center to Stop Trial

Mary K. Caffrey

Moffitt Cancer Center said there's nothing wrong with the drug, but a spokesman said the trial is halted for now pending the outcome of the investigation.

December 28th 2015

Cancer's Toll Beyond the Disease: Medical Costs and Productivity

Surabhi Dangi-Garimella, PhD

A new study published by the American Cancer Society found that younger colorectal cancer survivors end up spending over $8500 annually in medical expenses and they also experience significantly greater loss of productivity compared with individuals without cancer.

December 26th 2015

This Week in Managed Care: December 26, 2015

This week The American Journal of Managed Care offers a special episode of highlights from the American Society of Hematology's annual meeting, including sessions on newly approved treatments, how the move to pay-for-performance affects hematologists, and the increasing role of patient-reported outcomes.

December 25th 2015

Most-Viewed Videos from AJMC for the Year 2015

Surabhi Dangi-Garimella, PhD

Top 10 videos from The American Journal of Managed Care's Summit and Insight programs.

December 23rd 2015

Rivaroxaban Safe and Effective in Cancer Patients With Thrombosis

Laura Joszt, MA

Although rivaroxaban was approved by the FDA in 2012, there has remained a knowledge gap about how it works with cancer patients. A recent study found that the therapy is safe and effective when used among patients with cancer.

December 22nd 2015

OB-GYN Groups Say Insurers' Genetic Testing Rules Limit Access to Care

Mary K. Caffrey

The statement from the obstetricians and gynecologists said that there aren't enough certified genetic counselors to meet demand. In a statement, the groups said this will limit access to care if patients must wait for assistance before ordering tests.

December 22nd 2015

Top 10 Articles from Evidence-Based Oncology for the Year 2015

Surabhi Dangi-Garimella, PhD

The most read articles in The American Journal of Managed Care's Evidence-Based Oncology ranged from personal narratives to healthcare policy issues that impact the broader population.

December 19th 2015

This Week in Managed Care: December 19, 2015

This week in managed care, Martin Shkreli, CEO of Turing Pharmaceuticals was arrested on charges of fraud; new research find that drug costs continue to take up a larger share of healthcare spending; and 3 healthcare experts take a look at how to fix the 340B drug pricing program.

December 18th 2015

Merck's Pembrolizumab Receives Approval for Expanded Indications

AJMC Staff

Pembrolizumab has been approved as first-line treatment for patients with unresectable or metastatic melanoma.

December 18th 2015

What We're Reading: Taxpayers Spending Millions on Expensive Generic Drugs

AJMC Staff

What we're reading, December 18, 2015: HHS report finds generic drug prices rising faster than inflation; UnitedHealthcare's real-time drug approval tool; and government overcharged by private Medicare Advantage plans.

December 18th 2015

Progress Toward Healthy People 2020: CDC Report Claims Reduction in Cancer Incidence

Surabhi Dangi-Garimella, PhD

Results of an analysis of 2012 cancer incidence and survival from various cancer registries, published in CDC's Morbidity and Mortality Weekly Report, indicates reduced incidence of overall cancer across the United States.

December 18th 2015

FDA Seeks Nationwide Ban on Letting Minors Use Tanning Beds

Mary K. Caffrey

Eleven states already ban minors from using tanning beds, and most states have other restrictions such as requiring a parent's permission.

December 17th 2015

Report Provides an Update on the 340B Drug Pricing Program

Surabhi Dangi-Garimella, PhD

A new report by the Berkeley Research Group provides numbers on Medicare Part B spending by 340B entities, especially for oncology drugs.

December 17th 2015

Need to Lower Drug Costs, Not the Size of the Donut Hole, for Medicare Beneficiaries With Cancer

Surabhi Dangi-Garimella, PhD

A study in the Journal of Clinical Oncology predicts financial stress on Medicare Part D beneficiaries on oral anticancer medicines, even after the expected closing of the donut hole in 2020.

December 16th 2015

Kadcyla and Opdivo Too Expensive for NICE

AJMC Staff

NICE rejects promising oncology agents once again, citing high drug cost.

December 16th 2015

FDA Updates: Oncology

Surabhi Dangi-Garimella, PhD

Several new FDA approvals and research advances in oncology have the potential for improved outcomes among cancer patients.

December 16th 2015

Managed Care Updates: Oncology

Surabhi Dangi-Garimella, PhD

Updates on screening age recommendations for mammograms, CDC report on a decline in smoking rates in the country, and regulation of laboratory-developed tests.

December 15th 2015

Dr Michael Kolodziej Outlines Ways to Reform 340B

There are 3 potential solutions for reforming the 340B drug pricing program, according to Michael Kolodziej, MD, national medical director of oncology solutions in the Office of the Chief Medical Officer at Aetna.

December 15th 2015

Choosing Wisely: Eliminating Unnecessary Biopsies

Surabhi Dangi-Garimella, PhD

A retrospective analysis of phase 1 oncology studies that used biopsy-derived pharmacodynamic biomarkers, could not draw a correlation between subsequent drug development and biopsy sample collection.

December 15th 2015

The Struggle Between Oncology Care Cost and Value

Joseph Alvarnas, MD

While cost is an important component of value, it tells only a small part of the cancer care story. By focusing on issues of payment and cost alone, we miss our opportunity to engage cancer care stakeholders in the process of creating a more effective system of care.

December 15th 2015

Patient Access to Oncology Care in ACA Exchange Plans

Caroline F. Pearson Deirdre B. Parsons, MPP, MPH, MS

This article describes provider networks and benefit design-including deductibles, cost-sharing, and maximum out-of-pocket limits-for oncology care in 2015 health insurance exchanges.

December 15th 2015

Healthcare Leaders Offer Solutions for Reforming 340B in New Issue of Evidence-Based Oncology

Depending on one's point of view, the 340B prescription drug program keeps safety net hospitals afloat or serves as a profit center at the expensive of community providers. Three leading voices-Rena M. Conti, PhD; Peter B. Bach, MD, MAPP; and Michael Kolodziej, MD; recommend reforms in the new issue of Evidence-Based Oncology, a publication of The American Journal of Managed Care.

December 15th 2015

PrecisionFDA Launched With Promise of Transparency and Quality Care

Surabhi Dangi-Garimella, PhD

The FDA, today, launched precisionFDA, a cloud-based platform that members can utilize to access and share data sets, analysis pipelines, and bioinformatics tools.

December 15th 2015

ACCC ICLIO meeting

Surabhi Dangi-Garimella, PhD

At the first annual conference of the Institute for Clinical Immuno-Oncology on October 1, 2015, in Philadelphia, the discussion revolved around integrating immuno-oncology into clinical practice and programs that assist with patient access to these treatments.

December 15th 2015

COA Payer Summit

Surabhi Dangi-Garimella, PhD

Providers and payers came together to discuss challenges and share success stories as they adapt to the changing healthcare realm.

December 14th 2015

Measuring Financial Toxicity in Cancer Patients

Pauline Lee, PharmD Jonas A. de Souza, MD

With the rising costs of cancer care, evidence-based tools can help physicians screen patients for financial toxicity.

...

115 116 117 118 119 120 121 122 123

...

187 >

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions